Resources

Cell and Gene Therapy Catapult (CGT Catapult), an independent technology and innovation organisation specialising in the advancement of the cell and gene therapy industry, has appointed Dr Ed Samuel as its Chief Operations Officer (COO).

Laverock Therapeutics closes additional seed funding round, bringing total raised to more than £20 million.

Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million) in the last nine months.

Ikarovec has highlighted the therapeutic potential of its approach in geographic atrophy and wet AMD, with presentations at major ophthalmic and gene therapy conferences.

eXmoor Pharma has entered into a strategic partnership with KU Leuven, one of Europe’s leading academic institutions, to support a new cell and gene therapy hub.

Ikarovec, which is developing field-changing bicistronic gene therapies for ophthalmic diseases, appoints Dr Thomas Ciulla, expert in ophthalmology drug development, as President and CEO.

Expanding Apprenticeship Pathways - Supporting RNA Medicines, oligos, Quality, Digital and Automation and Manufacturing through ATAC.

o2h discovery is excited to announce Ubiquigent as a winner of the o2h Kickstarter Competition. Ubiquigent Limited (Ubiquigent), a revenue- and IP-generating drug discovery company dedicated to enabling deubiquitinase (DUB)-focused drug discovery.

RoslinCT has entered into a strategic partnership with Gamida Cell Ltd. to manufacture their FDA-Approved Cell Therapy Omisirge.®

The UKHSA Conference 2025, delivered in partnership with the FPH, will explore the full breadth of UKHSA’s work; from science-driven research to effective policy implementation.

Rare Disease Day marks an important occasion to raise awareness of rare diseases and the need for action to support people and families living with these conditions.

A new network will foster collaboration among regulators, industry, and researchers to ensure there is a world-leading regulatory environment in the UK for advanced therapies that supports companies in the development, trial, and launch of these innovative treatments.

Accession Therapeutics obtains approval for first TROCEPT cancer clinical trial in UK.

The Milner Therapeutics Institute are delighted to announce a new collaboration with Flagship Pioneering and Cambridge University Health Partners (CUHP), to jointly advance breakthrough scientific research and technologies.

£20 million Series A financing underway to support development of lead product

Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials.

Excelra has partnered with Orogen Therapeutics, an innovative DNA-Encoded Library (DEL) and AI-driven biotechnology company currently developing a portfolio of best-in-class small molecule treatments.